Dan Polen - Polen Capital Management
Holding/activity history for Regeneron Pharmaceuticals (REGN)
| Period | Shares | % of Portfolio | Activity | % Change to Portfolio | Reported Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2022 Q2 | 0 | 0.00 | Sell 100.00% | <0.01 | SEC | ||
| 2022 Q1 | 1,383 | <0.01 | Reduce 28.64% | <0.01 | $698.48 | $966,000 | SEC |
| 2021 Q4 | 1,938 | <0.01 | Reduce 10.07% | <0.01 | $631.58 | $1,224,000 | SEC |
| 2021 Q3 | 2,155 | <0.01 | Buy | <0.01 | $605.10 | $1,304,000 | SEC |
| 2021 Q1 | 0 | 0.00 | Sell 100.00% | 2.25 | SEC | ||
| 2020 Q4 | 2,002,804 | 2.25 | Add 3.36% | 0.07 | $483.11 | $967,575,000 | SEC |
| 2020 Q3 | 1,937,657 | 2.91 | Add 5.05% | 0.14 | $559.78 | $1,084,662,000 | SEC |
| 2020 Q2 | 1,844,534 | 3.48 | Add 7.18% | 0.23 | $623.65 | $1,150,343,000 | SEC |
| 2020 Q1 | 1,721,002 | 3.65 | Add 2.67% | 0.09 | $488.29 | $840,348,000 | SEC |
| 2019 Q4 | 1,676,294 | 2.48 | Add 2.08% | 0.05 | $375.48 | $629,415,000 | SEC |
| 2019 Q3 | 1,642,210 | 2.10 | Add 3.60% | 0.07 | $277.40 | $455,549,000 | SEC |
| 2019 Q2 | 1,585,113 | 2.41 | Reduce 1.09% | 0.04 | $313.00 | $496,140,000 | SEC |
| 2019 Q1 | 1,602,561 | 3.44 | Add 7.90% | 0.25 | $410.62 | $658,044,000 | SEC |
| 2018 Q4 | 1,485,255 | 3.62 | Reduce 0.22% | <0.01 | $373.50 | $554,743,000 | SEC |
| 2018 Q3 | 1,488,492 | 3.42 | Add 0.33% | 0.01 | $404.04 | $601,410,000 | SEC |
| 2018 Q2 | 1,483,634 | 3.29 | Add 4.54% | 0.14 | $344.99 | $511,839,000 | SEC |
| 2018 Q1 | 1,419,141 | 3.47 | Add 2.13% | 0.07 | $344.36 | $488,695,000 | SEC |
| 2017 Q4 | 1,389,545 | 3.88 | Add 1.16% | 0.04 | $375.96 | $522,413,000 | SEC |
| 2017 Q3 | 1,373,614 | 4.94 | Reduce 13.41% | 0.91 | $447.12 | $614,170,000 | SEC |
| 2017 Q2 | 1,586,320 | 6.81 | Add 7.34% | 0.47 | $491.14 | $779,105,000 | SEC |
| 2017 Q1 | 1,477,907 | 5.33 | Add 10.24% | 0.50 | $387.51 | $572,704,000 | SEC |
| 2016 Q4 | 1,340,649 | 5.42 | Add 65.25% | 2.14 | $367.09 | $492,139,000 | SEC |
| 2016 Q3 | 811,301 | 3.89 | Add 2.97% | 0.11 | $402.02 | $326,159,000 | SEC |
| 2016 Q2 | 787,870 | 3.49 | Add 11.58% | 0.36 | $349.23 | $275,148,000 | SEC |
| 2016 Q1 | 706,090 | 3.49 | Add 12.85% | 0.40 | $360.44 | $254,503,000 | SEC |
| 2015 Q4 | 625,697 | 5.25 | Add 8.72% | 0.42 | $542.87 | $339,672,000 | SEC |
| 2015 Q3 | 575,505 | 4.91 | Add 3.70% | 0.18 | $465.14 | $267,690,000 | SEC |
| 2015 Q2 | 554,959 | 5.48 | Reduce 2.10% | 0.10 | $510.13 | $283,101,000 | SEC |
| 2015 Q1 | 566,865 | 4.99 | Add 4.53% | 0.22 | $451.48 | $255,928,000 | SEC |
| 2014 Q4 | 542,293 | 4.58 | Reduce 1.74% | 0.08 | $410.25 | $222,476,000 | SEC |
| 2014 Q3 | 551,902 | 4.47 | Add 164.59% | 2.78 | $360.52 | $198,972,000 | SEC |
| 2014 Q2 | 208,590 | 1.29 | Reduce 4.82% | 0.07 | $282.47 | $58,920,000 | SEC |
| 2014 Q1 | 219,163 | 1.42 | Add 12,416.45% | 1.41 | $300.28 | $65,810,000 | SEC |
| 2013 Q4 | 1,751 | 0.01 | $275.27 | $482,000 | SEC | ||
| 2013 Q3 | 1,751 | 0.01 | $312.96 | $548,000 | SEC | ||
| 2013 Q2 | 1,751 | 0.01 | Buy | 0.01 | $225.01 | $394,000 | SEC |